Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Economic assessment of pulsed dose-rate (PDR) brachytherapy with optimized dose distribution for cervix carcinoma].
Remonnay R, Morelle M, Pommier P, Haie-Meder C, Quetin P, Kerr C, Delannes M, Castelain B, Peignaux K, Kirova Y, Romestaing P, Williaume D, Krzisch C, Thomas L, Lang P, Baron MH, Cussac A, Lesaunier F, Maillard S, Barillot I, Charra-Brunaud C, Carrère MO, Peiffert D. Remonnay R, et al. Among authors: maillard s. Cancer Radiother. 2010 Jun;14(3):161-8. doi: 10.1016/j.canrad.2009.11.004. Epub 2010 Mar 4. Cancer Radiother. 2010. PMID: 20206571 Clinical Trial. French.
Harmonization of practices between radiotherapy centres in the Nord and Pas-de-Calais regions (France): A three-year evaluation.
Pasquier D, Darloy F, Dewas S, Gras L, Maillard S, Rhliouch H, Tokarski M, Wagner JP, Degrendel-Courtecuisse AC, Dufour C, Fares M, Gilbeau L, Olszyk O, Castelain B, Lartigau É. Pasquier D, et al. Among authors: maillard s. Cancer Radiother. 2019 Feb;23(1):10-16. doi: 10.1016/j.canrad.2018.03.007. Epub 2019 Jan 11. Cancer Radiother. 2019. PMID: 30639377
PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients.
de la Rochefordiere A, Kamal M, Floquet A, Thomas L, Petrow P, Petit T, Pop M, Fabbro M, Kerr C, Joly F, Sevin E, Maillard S, Curé H, Weber B, Brunaud C, Minsat M, Gonzague L, Berton-Rigaud D, Aumont M, Gladieff L, Peignaux K, Bernard V, Leroy Q, Bieche I, Margogne A, Nadan A, Fourchotte V, Diallo A, Asselain B, Plancher C, Armanet S, Beuzeboc P, Scholl SM. de la Rochefordiere A, et al. Among authors: maillard s. Clin Cancer Res. 2015 Jun 1;21(11):2530-7. doi: 10.1158/1078-0432.CCR-14-2368. Epub 2015 Feb 27. Clin Cancer Res. 2015. PMID: 25724520 Clinical Trial.
[Postoperative radiotherapy in N0 laryngeal cancer].
Maillard S, Jovenin N, Cauchois A, Froissart D, Merol JC, Chays A, Nguyen TD. Maillard S, et al. Cancer Radiother. 2005 Sep;9(5):285-92. doi: 10.1016/j.canrad.2005.05.004. Epub 2005 Sep 15. Cancer Radiother. 2005. PMID: 16168697 French.
High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes.
Giro C, Berger B, Bölke E, Ciernik IF, Duprez F, Locati L, Maillard S, Ozsahin M, Pfeffer R, Robertson AG, Langendijk JA, Budach W. Giro C, et al. Among authors: maillard s. Radiother Oncol. 2009 Feb;90(2):166-71. doi: 10.1016/j.radonc.2008.09.007. Epub 2008 Oct 30. Radiother Oncol. 2009. PMID: 18977050
Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study.
Papeix C, Castelnovo G, Leray E, Coustans M, Levy P, Visy JM, Kobelt G, Lamy F, Allaf B, Heintzmann F, Chouette I, Raponi E, Durand B, Grevat E, Kamar D, Debouverie M, Lebrun-Frenay C; Virgile Study Group. Papeix C, et al. Neurol Ther. 2022 Jun;11(2):633-658. doi: 10.1007/s40120-022-00334-y. Epub 2022 Feb 11. Neurol Ther. 2022. PMID: 35147904 Free PMC article.
105 results